Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.

BACKGROUND Hepatorenal syndrome (HRS) is a severe complication of cirrhosis and is associated with high mortality. Ornipressin and terlipressin are effective in treatment of HRS, but are not available in the USA. The efficacy of vasopressin (AVP) and octreotide (OCT) infusions, commonly utilized in the USA, in the treatment of HRS is unknown. This study aims to evaluate the effects of AVP and OCT on renal function, systemic haemodynamics and clinical outcomes in HRS. METHODS This observational study evaluated patients receiving AVP or OCT therapy for HRS from January 2000 to December 2003. Recovery from HRS was defined as a decrease in the serum creatinine (SCr) to a value < or =1.5 mg/dl. RESULTS Forty-three patients were identified: eight received AVP, 16 received OCT and 19 received both AVP and OCT. Patients who received AVP alone or in combination with OCT had significantly greater recovery rates than those receiving OCT monotherapy (42 vs 38 vs 0%, respectively, P = 0.01). The average time to response in serum creatinine (SCr) was 7+/- 2 days. The mean AVP doses were 0.23+/-0.19 U/min in patients demonstrating clinical response. Therapy with AVP was an independent predictor of recovery (odds ratio 6.4, 95% confidence interval 1.3-31.8). Patients who responded to therapy had significantly lower mortality (23 vs 67%, P = 0.008) and higher rates of liver transplantation (23 vs 0%, P = 0.005). No adverse effects related to AVP therapy were observed. CONCLUSION When compared with OCT, HRS patients treated with AVP had significantly higher recovery rates, improved survival and were more likely to receive a liver transplant.

[1]  R. MacLaren,et al.  Effects of Continuous Vasopressin Infusion in Patients with Septic Shock , 2004, The Annals of pharmacotherapy.

[2]  F. Wong,et al.  Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.

[3]  E. Savage,et al.  Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock* , 2004, Critical care medicine.

[4]  M. Navasa,et al.  Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. , 2004, Journal of hepatology.

[5]  M. Lafortune,et al.  Octreotide in hepatorenal syndrome: A randomized, double‐blind, placebo‐controlled, crossover study , 2003, Hepatology.

[6]  M. Dünser,et al.  Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors* , 2003, Critical care medicine.

[7]  R. Gupta,et al.  Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial , 2003, Journal of gastroenterology and hepatology.

[8]  R. Bataller,et al.  Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study , 2002, Hepatology.

[9]  P. Fiévet,et al.  Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study* , 2002, European journal of gastroenterology & hepatology.

[10]  R. Bataller,et al.  Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. , 2000, Journal of hepatology.

[11]  A. Gerbes,et al.  Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine , 1999, Hepatology.

[12]  P. Angeli,et al.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.

[13]  E. Casiglia,et al.  Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites , 1998, Hepatology.

[14]  Rosa Gilabert,et al.  Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems , 1998, Hepatology.

[15]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[16]  J. Henriksen,et al.  Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. , 1997, Journal of hepatology.

[17]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[18]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[19]  D. V. van Thiel,et al.  Effects of renal impairment on liver transplantation. , 1987, Gastroenterology.

[20]  D. Brooks,et al.  Central adrenergic control of vasopressin release. , 1986, Neuroendocrinology.